c-flip protein expression in Burkitt's lymphomas is associated with a poor clinical outcome

British Journal of Haematology

Volumn 128, Issue 6, 2005, Pages 767-773

  Valnet Rabier, Marie Blanche ^a   Challier, Bruno ^a   Thiebault, Sylvie ^b   Angonin, Régis ^a   Margueritte, Geneviève ^c   Mougin, Christiane ^a   Kantelip, Bernadette ^a   Deconinck, Eric ^a   Cahn, Jean Yves ^a   Fest, Thierry ^a,d  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b Pathology Department   (France)

^c MONTPELLIER UNIVERSITY HOSPITAL   (France)

^d PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Burkitt's lymphoma; c Flip; CD95

Indexed keywords

CASPASE; CASPASE 3A; ENZYME PRECURSOR; FAS ANTIGEN; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PARAFFIN; PROCASPASE 8; PROTEIN P53; SURVIVIN; TRANSCRIPTION FACTOR RELA; TUMOR MARKER; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BURKITT LYMPHOMA; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SCHOOL CHILD;

ADULT; ANTIGENS, CD95; APOPTOSIS; BURKITT LYMPHOMA; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 20144388169     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05378.x     Document Type: Article

References (37)

1. Algeciras-Schimnich, A. & Peter, M.E. (2003) Actin dependent CD95 internalization is specific for type I cells. FEBS Letters, 546, 185-188.
2. Algeciras-Schimnich, A., Pietras, E.M., Barnhart, B.C., Legembre, P., Vijayan, S., Holbeck, S.L. & Peter, M.E. (2003) Two CD95 tumor classes with different sensitivities to antitumor drugs. Proceedings of the National Academy of Sciences of the United States of America, 100, 11445-11450.
3. Blum, K.A., Lozanski, G. & Byrd, J.C. (2004) Adult Burkitt's leukemia and lymphoma. Blood, 104, 3009-3020.
4. Debatin, K.M. (2004) Apoptosis pathways in cancer and cancer therapy. Cancer Immunology Immunotherapy, 53, 153-159.
5. Djerbi, M., Screpanti, V., Catrina, A.I., Bogen, B., Biberfeld, P. & Grandien, A. (1999) The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. Journal of Experimental Medicine, 190, 1025-1032.
6. Ferreira, G.G., Span, S.W., Peters, G.J., Kruyt, F.A. & Giaccone, G. (2000) Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460. Cancer Research, 60, 7133-7141.
7. Friedrich, K., Wieder, T., Von Haefen, C., Radetzki, S., Janicke, R., Schulze-Osthoff, K., Dorken, B. & Daniel, P.T. (2001) Overexpression of caspase-3 restores sensitivity for drug-induced apoptosis in breast cancer cell lines with acquired drug resistance. Oncogene, 20, 2749-2760.
8. Fulda, S., Meyer, E., Friesen, C., Susin, S.A., Kroemer, G. & Debatin, K.M. (2001) Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis. Oncogene, 20, 1063-1075.
9. Gerard-Marchand, R.H.I. & Lennert, K. (1974) Classification of non-Hodgkin's lymphomas. Lancet, 2, 406-408.
10. Gregory, C.D., Tursz, T., Edwards, C.F., Tetaud, C., Talbot, M., Caillou, B., Rickinson, A.B. & Lipinski, M. (1987) Identification of a subset of normal B cells with a Burkitt's lymphoma (BL)-like phenotype. Journal of Immunology, 139, 313-318.
11. Gutierrez, M.I., Cherney, B., Hussain, A., Mostowski, H., Tosato, G., Magrath, I. & Bhatia, K. (1999) Bax is frequently compromised in Burkitt's lymphomas with irreversible resistance to Fas-induced apoptosis. Cancer Research, 59, 696-703.
12. Harris, N.L., Jaffe, E.S., Stein, H., Banks, P.M., Chan, J.K., Cleary, M.L., Delsol, G., De Wolf-Peeters, C., Falini, B. & Gatter, K.C. (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood, 84, 1361-1392.
13. Haynes, A.P., Daniels, I., Abhulayha, A.M., Carter, G.I., Metheringham, R., Gregory, C.D. & Thomson, B.J. (2002) CD95 (Fas) expression is regulated by sequestration in the Golgi complex in B-cell lymphoma. British Journal of Haematology, 118, 488-494.
14. Hengartner, M.O. (2000) The biochemistry of apoptosis. Nature, 407, 770-776.
15. Houldsworth, J., Xiao, H., Murty, V.V., Chen, W., Ray, B., Reuter, V.E., Bosl, G.J. & Chaganti, R.S. (1998) Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. Oncogene, 16, 2345-2349.
16. Irisarri, M., Plumas, J., Bonnefoix, T., Jacob, M.C., Roucard, C., Pasquier, M.A., Sotto, J.J. & Lajmanovich, A. (2000) Resistance to CD95-mediated apoptosis through constitutive c-Flip expression in a non-Hodgkin's lymphoma B cell line. Leukemia, 14, 2149-2158.
17. Irmler, M., Thome, M., Hahne, M., Schneider, P., Hofmann, K., Steiner, V., Bodmer, J.L., Schroter, M., Burns, K., Mattmann, C., Rimoldi, D., French, L.E. & Tschopp, J. (1997) Inhibition of death receptor signals by cellular Flip. Nature, 388, 190-195.
18. Jaffe, E.S., Harris, N.L., Stein, H. & Vardiman, J.W. (2001) World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. IARC, Lyon, France.
19. Jones, D.T., Ganeshaguru, K., Virchis, A.E., Folarin, N.I., Lowdell, M.W., Mehta, A.B., Prentice, H.G., Hoffbrand, A.V. & Wickremasinghe, R.G. (2001) Caspase 8 activation independent of Fas (CD95/APO-1) signaling may mediate killing of B-chronic lymphocytic leukemia cells by cytotoxic drugs or gamma radiation. Blood, 98, 2800-2807.
20. Kaufmann, S.H. & Earnshaw, W.C. (2000) Induction of apoptosis by cancer chemotherapy. Experimental Cell Research, 256, 42-49.
21. Kuppers, R., Klein, U., Schwering, I., Distler, V., Brauninger, A., Cattoretti, G., Tu, Y., Stolovitzky, G.A., Califano, A., Hansmann, M.L. & Dalla-Favera, R. (2003) Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. Journal of Clinical Investigation, 111, 529-537.
22. Lennert, K. (1978) Malignant Lymphomas other than Hodgkin's Disease. Springer Verlag, New York, USA.
23. Liu, Y.J., Mason, D.Y., Johnson, G.D., Abbot, S., Gregory, C.D., Hardie, D.L., Gordon, J. & MacLennan, I.C. (1991) Germinal center cells express bcl-2 protein after activation by signals which prevent their entry into apoptosis. European Journal of Immunology, 21, 1905-1910.
24. Malta, H., Eby, M.T., Gazdar, A.F. & Chaudhary, P.M. (2002) Role of MRIT/c-Flip in protection against chemotherapy-induced apoptosis. Cancer Biology and Therapy, 1, 652-660.
25. Medema, J.P., Scaffidi, C., Kischkel, F.C., Shevchenko, A., Mann, M., Krammer, P.H. & Peter, M.E. (1997) FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO Journal, 16, 2794-2804.
26. Micheau, O., Lens, S., Gaide, O., Alevizopoulos, K. & Tschopp, J. (2001) NF-kappaB signals induce the expression of c-Flip. Molecular and Cellular Biology, 21, 5299-5305.
27. Pedersen, I.M., Kitada, S., Schimmer, A., Kim, Y., Zapata, J.M., Charboneau, L., Rassenti, L., Andreeff, M., Bennett, F., Sporn, M.B., Liotta, L.D., Kipps, T.J. & Reed, J.C. (2002) The triterpenoid CDDO induces apoptosis in refractory CLL B cells. Blood, 100, 2965-2972.
28. Preudhomme, C., Dervite, L., Wattel, E., Vanrumbeke, M., Flactif, M., Lai, I.L., Hecquet, B., Coppin, M.C., Nelken, B. & Gosselin, B. (1995) Clinical significance of p53 mutations in newly diagnosed Burkitt's lymphoma and acute lymphoblastic leukemia: a report of 48 cases. Journal of Clinical Oncology, 13, 812-820.
29. Roy, S. & Nicholson, D.W. (2000) Cross-talk in cell death signaling. Journal of Experimental Medicine, 192, 21-26.
30. Scaffidi, C., Schmitz, I., Krammer, P.H. & Peter, M.E. (1999) The role of c-Flip in modulation of CD95-induced apoptosis. Journal of Biological Chemistry, 274, 1541-1548.
31. Solary, E., Droin, N., Bettaieb, A., Corcos, L., Dimanche-Boitrel, M.T. & Garrido, C. (2000) Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies. Leukemia, 14, 1833-1849.
32. Soussain, C., Patte, C., Ostronoff, M., Delmer, A., Rigal-Huguet, F., Cambier, N., Leprise, P.Y., Francois, S., Cony-Makhoul, P., Harousseau, J.L., Janvier, M., Chauvenel, L., Witz, F. & Pico, J. (1995) Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood, 85, 664-674.
33. Tepper, C.G. & Seldin, M.F. (1999) Modulation of caspase-8 and FLICE-inhibitory protein expression as a potential mechanism of Epstein-Barr virus tumorigenesis in Burkitt's lymphoma. Blood, 94, 1727-1737.
34. Thome, M., Schneider, P., Hofmann, K., Fickenscher, H., Meinl, E., Neipel, F., Mattmann, C., Burns, K., Bodmer, J.L., Schroter, M., Scaffidi, C., Krammer, P.H., Peter, M.E. & Tschopp, J. (1997) Viral FLICE-inhibitory proteins (Flips) prevent apoptosis induced by death receptors. Nature, 386, 517-521.
35. Wesselborg, S., Engels, I.H., Rossmann, E., Los, M. & Schulze-Osthoff, K. (1999) Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction. Blood, 93, 3053-3063.
36. Wieder, T., Essmann, F., Prokop, A., Schmelz, K., Schulze-Osthoff, K., Beyaert, R., Dorken, B. & Daniel, P.T. (2001) Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3. Blood, 97, 1378-1387.
37. Wilson, W.H., Teruya-Feldstein, J., Fest, T., Harris, C., Steinberg, S.M., Jaffe, E.S. & Raffeld, M. (1997) Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood, 89, 601-609.